Press releases
- 4basebio Plc - 4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client's vaccine program
- 4basebio Plc - 4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine
- 4basebio Plc - 4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI's tender process for supplying its RNA Centre of Excellence
Key statistics
On Friday, 4Basebio PLC (88Q:BER) closed at 16.70, -2.91% below its 52-week high of 17.20, set on May 15, 2024.
52-week range
Open | 16.50 |
---|---|
High | 16.70 |
Low | 16.20 |
Bid | 15.70 |
Offer | 17.70 |
Previous close | 16.60 |
Average volume | 80.00 |
---|---|
Shares outstanding | 12.81m |
Free float | 3.89m |
P/E (TTM) | -- |
Market cap | 183.75m GBP |
EPS (TTM) | -0.5094 GBP |
Data delayed at least 15 minutes, as of May 17 2024 20:33 BST.
More ▼